Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

To assess the medium-term performance of the Uretex Urethral Support System, patients were evaluated by the 1-h pad test, cough stress test (CST), Valsalva leak-point pressure test (VLPP), and validated questionnaires. Seventy-five patients were enrolled; median follow-up was 3.6 years (range, 3.1-4.3 years). All patients had a negative CST, 65 (87%) had no leakage during VLPP, and 62 of 72 patients (86%) had a negative 1-h pad test. Compared with baseline values of 50.0 and 28.6, median Urogenital Distress Inventory and Incontinence Impact Questionnaire-7 scores at 3-year follow-up were 16.7 and 0, respectively (P < 0.001). Observed medium-term morbidity included de novo urgency in four (5%), frequency in three (4%), and urge incontinence in one (1%). No patients reported graft erosion. The Uretex Urethral Support System is highly effective (both objectively and subjectively) for treatment of stress urinary incontinence and improves quality of life in women with minimal adverse sequelae.

Written by
Gebhart JB, Dixon DA, Trabuco EC, Klingele CJ, Bagniewski SM, Weaver AL.

Reference
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Feb 28. Epub ahead of print.
doi:10.1007/s00192-008-0578-y

PubMed Abstract
PMID:18305884

UroToday.com Stress Urinary Incontinence Section

Please log-in or register in order to submit comments.

Powered by AkoComment!